Novelgen
Find Us
← Back to list
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal

Pfizer leaps into ‘in vivo’ CAR-T with latest China deal

BioPharma DiveKristin JensenNovember 18, 2026
The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
Read original article
← Back to list